<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430092</url>
  </required_header>
  <id_info>
    <org_study_id>ST-601A-002b</org_study_id>
    <nct_id>NCT00430092</nct_id>
  </id_info>
  <brief_title>Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirion Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this phase III study is to determine the efficacy of difluprednate in the
      treatment of inflammation following ocular surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Chamber Cell Grade of &quot;0&quot; on Day 8 (Difluprednate QID vs Placebo).</measure>
    <time_frame>Day 8 (QID)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Difluprednate 0.05% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Difluprednate 0.05% 1 drop BID for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Difluprednate 0.05% QID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Difluprednate 0.05% 1 drop QID for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluprednate</intervention_name>
    <arm_group_label>Difluprednate 0.05% BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Difluprednate</intervention_name>
    <arm_group_label>Difluprednate 0.05% QID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral ocular surgery in the day prior to study enrollment.

          -  Anterior chamber cell grade ≥ &quot;2&quot; on the day after surgery (Day 1).

          -  Aged 2 years or older on the day of consent.

          -  Negative urine pregnancy test on Day 1 for postmenarchal subjects; negative urine
             pregnancy test for premenarchal subjects at the investigator's discretion.

          -  Provide signed written consent prior to entering the study or signed written consent
             from parent or legal guardian if subject is a minor and signed assent from minor
             subject, if appropriate.

        Presurgical Exclusion Criteria:

          -  Systemic administration of any corticosteroid in the 2 weeks prior to study
             enrollment.

          -  Periocular injection in the study eye of any corticosteroid solution within 4 weeks
             prior to instillation of the study drug, or of any corticosteroid depot within 2
             months prior to instillation of the study drug.

          -  Instillation of any topical ocular corticosteroid or NSAID within 24 hours prior to
             instillation of the study drug or during the course of the study, with the exception
             of presurgical administration of a topical NSAID to prevent miosis.

          -  Any history of glaucoma or ocular hypertension in the study eye.

          -  History or presence of endogenous uveitis.

          -  Any current corneal abrasion or ulceration.

          -  Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival
             disease.

          -  Allergy to similar drugs, such as other corticosteroids.

          -  History of steroid-related IOP increase.

          -  Scheduled surgery on the contralateral eye during the treatment period.

          -  Unwilling to discontinue use of contact lenses during the study period.

          -  Pregnancy or lactation.

          -  Participation in any study of an investigational topical or systemic new drug or
             device within 30 days prior to screening, or at any time during the study.

          -  Prior participation in the study described in this protocol.

          -  Unable or unwilling to give signed informed consent prior to participation in any
             study related procedures.

        Postsurgical Exclusion Criteria:

          -  Ocular hemorrhage which interferes with evaluation of postsurgery inflammation.

          -  Injection of gas into the vitreous body during surgery.

          -  Presence of IOP ≥24 mm Hg on Day 1 after surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Roger Vogel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sirion Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Eye Care</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <results_first_submitted>May 12, 2009</results_first_submitted>
  <results_first_submitted_qc>May 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2009</results_first_posted>
  <last_update_submitted>May 12, 2009</last_update_submitted>
  <last_update_submitted_qc>May 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Difluprednate</mesh_term>
    <mesh_term>Fluprednisolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject enrolled January 24, 2007 and last subject completed September 20, 2007 at 11 sites in the United States.</recruitment_details>
      <pre_assignment_details>Subjects enrolled if, 24 hours after ocular surgery, they had an anterior chamber cell grade of ≥ “2” and met the protocol inclusion and exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Difluprednate 0.05% BID</title>
          <description>Difluprednate 0.05% 1 drop BID for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Difluprednate 0.05% QID</title>
          <description>Difluprednate 0.05% 1 drop QID for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Difluprednate 0.05% BID</title>
          <description>Difluprednate 0.05% 1 drop BID for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Difluprednate 0.05% QID</title>
          <description>Difluprednate 0.05% 1 drop QID for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="113"/>
            <count group_id="B4" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.7" spread="0"/>
                    <measurement group_id="B2" value="68.4" spread="0"/>
                    <measurement group_id="B3" value="69.9" spread="0"/>
                    <measurement group_id="B4" value="69.8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="129.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anterior Chamber Cell Grade of “0” on Day 8 (Difluprednate QID vs Placebo).</title>
        <description>Measured on a 0 to 4 scale: “0” is ≤ 1 cell; “1” is 2-10 cells; “2” is 11-20 cells; “3” is 21-50 cells; “4” is &gt; 50 cells.</description>
        <time_frame>Day 8 (QID)</time_frame>
        <population>The ITT population was defined as all randomized subjects who received at least 1 administration of the study drug. Analysis of the ITT population, with LOCF for missing data, was conducted for all primary and secondary endpoints at Days 3, 8, 15, and 29.</population>
        <group_list>
          <group group_id="O1">
            <title>Difluprednate 0.05% BID</title>
            <description>Difluprednate 0.05% 1 drop BID for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Difluprednate 0.05% QID</title>
            <description>Difluprednate 0.05% 1 drop QID for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.</description>
          </group>
        </group_list>
        <measure>
          <title>Anterior Chamber Cell Grade of “0” on Day 8 (Difluprednate QID vs Placebo).</title>
          <description>Measured on a 0 to 4 scale: “0” is ≤ 1 cell; “1” is 2-10 cells; “2” is 11-20 cells; “3” is 21-50 cells; “4” is &gt; 50 cells.</description>
          <population>The ITT population was defined as all randomized subjects who received at least 1 administration of the study drug. Analysis of the ITT population, with LOCF for missing data, was conducted for all primary and secondary endpoints at Days 3, 8, 15, and 29.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of Subjects w/AC cell grade=0 on Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeremy Brace</name_or_title>
      <organization>Sirion Therapeutics, Inc.</organization>
      <phone>813-496-7325 ext 343</phone>
      <email>jbrace@siriontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

